All In Biotech

Drug Trial Radar · NCT00645671

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

A Randomized Multicenter, Double-Masked, Parallel-Group Clinical Safety and Efficacy Evaluation of Loteprednol Etabonate Ophthalmic Ointment, 0.5% Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

Last checked: Nov 19, 2026Latest source record: Mar 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

400

Actual

Start

Mar 2008

Primary completion

Mar 2009

Study completion Mar 2009

Sponsor

Lead sponsor
Bausch & Lomb IncorporatedIndustry
Sponsor type
Industry
First posted
Mar 28, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery

Conditions

  • Ocular Inflammation

Interventions

  • 0.5% Loteprednol Etabonate Ophthalmic OintmentDrug

    1/2 inch ribbon four times a day for 14 days

  • Vehicle of Loteprednol Etabonate Ophthalmic OintmentDrug

    1/2 inch ribbon four times a day for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.Time frame: Postoperative Day 8 (Visit 5)
  2. Grade 0 for PainTime frame: Postoperative Day 8 (Visit 5)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • John Hunkeler, MD

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.